PURPOSE: Late night salivary cortisol (LNSC) is useful for diagnosing hypercortisolism and monitoring patients with Cushing's disease (CD) following pituitary surgery. It may also be a better index of cortisol secretion than serum cortisol or urinary free cortisol (UFC). No data regarding the role of LNSC in the early monitoring of patients with CD receiving drug therapy has been published. We investigated the value of LNSC in monitoring the short-term efficacy of pasireotide. METHODS: Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis. Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days. LNSC and UFC levels were assessed at baseline and day 15. RESULTS: At baseline, all patients had elevated LNSC which was correlated significantly with UFC levels (r = 0.97, P = .0002). At day 15, LNSC was reduced in six patients. LNSC decreases were observed from day 1 (-20%) and persisted until day 15 (overall mean reduction from baseline -51%), with the greatest decrease on day 5 (-58%). At day 15, UFC levels were decreased in all patients and normalized in one that restored also salivary cortisol rhythm. CONCLUSIONS: In patients with CD, pasireotide rapidly reduced and normalized both UFC and LNSC levels. LNSC may be a simple, non-invasive biomarker to assess the early response to pasireotide, particularly in determining whether cortisol rhythm is normalized in patients with normalized UFC levels. Further studies are warranted.
PURPOSE: Late night salivary cortisol (LNSC) is useful for diagnosing hypercortisolism and monitoring patients with Cushing's disease (CD) following pituitary surgery. It may also be a better index of cortisol secretion than serum cortisol or urinary free cortisol (UFC). No data regarding the role of LNSC in the early monitoring of patients with CD receiving drug therapy has been published. We investigated the value of LNSC in monitoring the short-term efficacy of pasireotide. METHODS: Seven patients who were enrolled in a phase II study investigating the efficacy of pasireotide in CD (CSOM230B2208) were included in this analysis. Patients self-administered subcutaneous pasireotide 600 μg bid for 15 days. LNSC and UFC levels were assessed at baseline and day 15. RESULTS: At baseline, all patients had elevated LNSC which was correlated significantly with UFC levels (r = 0.97, P = .0002). At day 15, LNSC was reduced in six patients. LNSC decreases were observed from day 1 (-20%) and persisted until day 15 (overall mean reduction from baseline -51%), with the greatest decrease on day 5 (-58%). At day 15, UFC levels were decreased in all patients and normalized in one that restored also salivary cortisol rhythm. CONCLUSIONS: In patients with CD, pasireotide rapidly reduced and normalized both UFC and LNSC levels. LNSC may be a simple, non-invasive biomarker to assess the early response to pasireotide, particularly in determining whether cortisol rhythm is normalized in patients with normalized UFC levels. Further studies are warranted.
Authors: Bo A G Jönsson; Birgitta Malmberg; Asa Amilon; Anne Helene Garde; Palle Orbaek Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2003-01-25 Impact factor: 3.205
Authors: Dalia L Batista; Xun Zhang; Roger Gejman; Peter J Ansell; Yunli Zhou; Sarah A Johnson; Brooke Swearingen; E Tessa Hedley-Whyte; Constantine A Stratakis; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2006-08-29 Impact factor: 5.958
Authors: Joost van der Hoek; Marlijn Waaijers; Peter M van Koetsveld; Diana Sprij-Mooij; Richard A Feelders; Herbert A Schmid; Philippe Schoeffter; Daniel Hoyer; Davide Cervia; John E Taylor; Michael D Culler; Steven W J Lamberts; Leo J Hofland Journal: Am J Physiol Endocrinol Metab Date: 2005-03-15 Impact factor: 4.310
Authors: Leo J Hofland; Joost van der Hoek; Richard Feelders; Maarten O van Aken; Peter M van Koetsveld; Marlijn Waaijers; Diana Sprij-Mooij; Christian Bruns; Gisbert Weckbecker; Wouter W de Herder; Albert Beckers; Steven W J Lamberts Journal: Eur J Endocrinol Date: 2005-04 Impact factor: 6.664
Authors: L Trementino; M Zilio; G Marcelli; G Michetti; M Barbot; F Ceccato; M Boscaro; C Scaroni; G Arnaldi Journal: Endocrine Date: 2014-12-11 Impact factor: 3.633
Authors: F Ceccato; G Marcelli; M Martino; C Concettoni; M Brugia; L Trementino; G Michetti; G Arnaldi Journal: J Endocrinol Invest Date: 2018-07-09 Impact factor: 4.256
Authors: John Newell-Price; Rosario Pivonello; Antoine Tabarin; Maria Fleseriu; Przemysław Witek; Mônica R Gadelha; Stephan Petersenn; Libuse Tauchmanova; Shoba Ravichandran; Pritam Gupta; André Lacroix; Beverly M K Biller Journal: Eur J Endocrinol Date: 2020-02 Impact factor: 6.664
Authors: James W Findling; Maria Fleseriu; John Newell-Price; Stephan Petersenn; Rosario Pivonello; Albert Kandra; Alberto M Pedroncelli; Beverly M K Biller Journal: Endocrine Date: 2016-05-21 Impact factor: 3.633